HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04566445 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

255

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.

Conditions

Dry Age-related Macular Degeneration

Interventions

DRUG: GT005

Sponsor

Gyroscope Therapeutics Limited

Collaborators

[object Object]